Followers | 48 |
Posts | 2221 |
Boards Moderated | 1 |
Alias Born | 01/28/2013 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, August 10, 2013 12:54:47 PM
So using some high level numbers for Novell, even say on $900 million in revenue and 10% of that. At a RR of 4% that is $3.6 million in revenue to DSS. He'll even at 5% of total revenues that is $1.8 million. These numbers are not immaterial to a company like DSS which has lost money prior to the merger.
That is precisely the problem. As I have stated previously, although Novell is certainly not the goliath that FB is (with LNKD a notch below FB), Novell as an entity is exponentially larger than both JIVE and BVSN combined. This is why I was concerned when no 8-K was issued by DSS re: the Novell settlement.
DSS mgmt (via their email communication to Justin Giles as he reported in his most recent SA article) also confirmed that in their determination, the Novell settlement was not material enough to merit an 8-K based upon SEC regs -- and keep in mind that the Novell settlement was agreed to on 7/18/13, which means that 2.5 months of royalties will hit in Q3, for which DSS is asserting this amount to be immaterial for the quarter.
According to your numbers, if only 10% of Novell's revenues were on the table, annual royalties to Bascom would be ~$3.6M, with monthly being ~$300k and quarterly being ~$900k. And, as you observed, with only the legacy business providing ongoing operating results, the only other contributors to earnings at ths time are the piddly royalty streams from JIVE and BVSN, which have been shown to be immaterial. As such, a settlement agreement that equates to $300k/mo or $900k/qtr or $3.6M per year for a company like DSS at this time is ABSOLUTELY MATERIAL.
Therefore, the only conclusion I can draw at this time (again, all speculation based upon very limited actual data points) is that the infringing revenue base for Novell must logically be much less than 10%.
But again, the prizes here are -- and have ALWAYS been -- FB and LNKD (with Salesforce again once the suit is re-filed)...
Recent DSS News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:15:31 PM
- Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition." • GlobeNewswire Inc. • 01/30/2024 01:05:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:54:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:05:40 PM
- DSS, Inc. Chairman Chan Acquires 672,173 shares of DSS In Open Market • GlobeNewswire Inc. • 01/04/2024 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:15:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:10:36 PM
- DSS, Inc. Announces Reverse Split as Part of NYSE American Compliance Plan • GlobeNewswire Inc. • 12/22/2023 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:30:23 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 12/13/2023 09:15:25 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 12/01/2023 09:15:06 PM
- Premier Packaging, a Wholly-Owned Subsidiary of DSS, Inc., Secures Contract Extension with Major Retailer Worth Up to $15 Million over Four Years • GlobeNewswire Inc. • 11/28/2023 01:10:00 PM
- DSS Inc. Wins Patent Dispute with Nichia Corporation • GlobeNewswire Inc. • 11/14/2023 01:00:00 PM
- DSS, Inc. Subsidiary Files Current Report on Form 8-K Disclosing Reverse Split of Outstanding and Issued Common Stock and Conversion of Certain Holder’s Common Stock • GlobeNewswire Inc. • 11/08/2023 01:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 09:25:10 PM
- DSS Inc. Receives Notice of Non-Compliance with NYSE American Trading Share Price Listing Rule • GlobeNewswire Inc. • 10/26/2023 09:25:00 PM
- DSS, Inc. Announces Filing of Registration Statement on Form S-1 for Initial Public Offering of Impact Biomedical • GlobeNewswire Inc. • 10/23/2023 12:25:00 PM
- DSS Inc. Issues Letter to Shareholders • GlobeNewswire Inc. • 10/12/2023 12:25:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 08:31:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:30:13 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/12/2023 08:30:20 PM
- DSS Inc. Expands DSS Wealth Management, Inc.'s Management Team for Ramp Up of Asset Management Subsidiary • GlobeNewswire Inc. • 09/06/2023 12:40:00 PM
- DSS Inc. Announces Distribution Date of August 8, 2023 for Spinoff of Impact BioMedical Inc. • GlobeNewswire Inc. • 07/31/2023 12:15:00 PM
- DSS Inc. Appoints Daniel Lew as Chief Investment Officer and Portfolio Manager for DSS Wealth, Inc. • GlobeNewswire Inc. • 07/05/2023 12:15:00 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM